Last quarter (Q3 2023), NervGen Pharma's total revenue was C$―, a decrease of ― from the same quarter last year. In Q3, NervGen Pharma's net income was C$-4.30M. See NervGen Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	C$ 0.00	C$ 0.00	C$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	C$ 12.90M	C$ 23.03M	C$ 12.81M	C$ 11.20M	C$ 8.24M	C$ 1.36M
Operating Income	C$ -12.90M	C$ -23.03M	C$ -12.81M	C$ -11.20M	C$ -8.24M	C$ -1.36M
Net Non Operating Interest Income Expense	C$ 427.53K	C$ -313.20K	C$ -29.42K	C$ 18.85K	C$ -1.37M	C$ 0.00
Other Income Expense	C$ 1.32M	C$ -1.91M	C$ 55.23K	C$ -9.11K	C$ -155.88K	-
Pretax Income	C$ -13.77M	C$ -20.72M	C$ -12.73M	C$ -11.19M	C$ -9.77M	C$ -1.36M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	C$ -13.77M	C$ -20.72M	C$ -12.73M	C$ -11.19M	C$ -9.77M	C$ -1.36M
Basic EPS	C$ -0.23	C$ -0.39	C$ -0.32	C$ -0.35	C$ -0.38	C$ -0.05
Diluted EPS	C$ -0.23	C$ -0.39	C$ -0.32	C$ -0.35	C$ -0.38	C$ -0.05
Basic Average Shares	C$ 177.59M	C$ 52.65M	C$ 39.29M	C$ 32.11M	C$ 25.90M	C$ 27.20M
Diluted Average Shares	C$ 177.59M	C$ 52.65M	C$ 39.29M	C$ 32.11M	C$ 25.90M	C$ 27.20M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	C$ 19.69M	C$ 23.03M	C$ -12.81M	C$ 11.20M	C$ 8.24M	C$ 1.36M
Net Income From Continuing And Discontinued Operation	C$ -13.77M	C$ -20.72M	C$ -12.73M	C$ -11.19M	C$ -9.77M	C$ -1.36M
Normalized Income	C$ -17.46M	C$ -15.23M	C$ -9.35M	C$ -11.18M	C$ -9.61M	C$ -1.36M
Interest Expense	-	-	-	-	-	-
EBIT	C$ -21.71M	C$ -20.21M	C$ -12.73M	C$ -11.20M	C$ -8.24M	C$ -1.36M
EBITDA	C$ -13.67M	C$ -20.09M	C$ -12.68M	C$ -11.16M	C$ -8.20M	C$ -1.34M

Currency in CAD

NervGen Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing